
Opinion|Videos|March 24, 2025
Patient’s Experience in Shared Decision Making in RRMM
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how patient involvement in multiple myeloma treatment decisions has evolved from a physician-directed approach to a collaborative partnership, with many patients now actively participating through researching options, joining support groups, asking questions about efficacy and side effects, and working with their health care team to balance quality of life considerations with treatment goals, though the degree of engagement varies based on patient preference, health literacy and physician communication style.
Advertisement
Video content above is prompted by the following:
- How involved have you been in the decision-making process for your treatment plan?
Advertisement
Related to this article

The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.

A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.

Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.

The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.

The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.

Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
Advertisement
Advertisement
Trending on CURE
1
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
2
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer
3
What Is a Personalized Cancer Vaccine? What Patients Should Know
4
New Tumor Type May Help Identify High-Risk Small Cell Lung Cancer
5

